Merck Went Own Way On Bezlotoxumab Endpoint And FDA May Not Follow

Merck rejected FDA's recommended endpoint to show efficacy in preventing C. difficile recurrence, which could make it difficult to gain approval for the product, headed to June 9 advisory panel review.